Stenocare ASFRA:S7C 40 Return-on-Tangible-Equity is -32.28% as of Mar. 2026. GuruFocus rates FRA:S7C with a GF Score™ of 40/100 and a GF Value™ of €0.29 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 901 Drug Manufacturers companies, Stenocare AS ranks worse than 85.9% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Stenocare AS's annualized net income for the quarter that ended in Mar. 2026 was €-0.24 Mil. Stenocare AS's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €0.76 Mil. Therefore, Stenocare AS's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -32.28%.
The historical rank and industry rank for Stenocare AS's Return-on-Tangible-Equity or its related term are showing as below:
FRA:S7C'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -308.65 Med: -43.17 Max: 10.03
Current: -23.49
During the past 8 years, Stenocare AS's highest Return-on-Tangible-Equity was 10.03%. The lowest was -308.65%. And the median was -43.17%.
FRA:S7C's Return-on-Tangible-Equity is ranked worse than 85.9% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs FRA:S7C: -23.49
Stenocare AS (FRA:S7C) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Stenocare AS Return-on-Tangible-Equity Related Terms
Stenocare AS Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Stenocare AS's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:S7C vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Stenocare AS's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stenocare AS Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Stenocare AS's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Stenocare AS's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -32.28% mean?
Stenocare AS (FRA:S7C) has a Return-on-Tangible-Equity of -32.28% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Stenocare AS and its competitors. According to the industry distribution chart, Stenocare AS ranks #774 out of 901 companies in the Drug Manufacturers industry, placing it in the top 85.9%.
Is Stenocare AS's Return-on-Tangible-Equity too high?
Stenocare AS's current Return-on-Tangible-Equity is -32.28%. Based on the distribution chart, Stenocare AS ranks #774 out of 901 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Stenocare AS has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Stenocare AS's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Stenocare AS ranks #774 out of 901 companies for Return-on-Tangible-Equity. This places Stenocare AS in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Stenocare AS and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stenocare AS's current Return-on-Tangible-Equity is -32.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stenocare AS stock overvalued right now?
Based on GuruFocus' analysis, Stenocare AS (FRA:S7C) is currently considered Possible Value Trap. The stock's GF Value™ is €0.29, compared to a current price of €0.13 — trading 56.9% below its estimated fair value. The current Return-on-Tangible-Equity is -32.28%. Stenocare AS's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Stenocare AS (FRA:S7C), the current Return-on-Tangible-Equity is -32.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stenocare AS (FRA:S7C) Overvalued in 2026?
Based on GuruFocus' analysis, Stenocare AS stock appears to be undervalued.
The current stock price of €0.13 is trading 56.9% below its estimated GF Value™ of €0.29.
GuruFocus considers Stenocare AS to be Possible Value Trap.
Key valuation signals for FRA:S7C:
Return-on-Tangible-Equity: -32.28%
GF Value™: €0.29 vs. price of €0.13 (56.9% below fair value)
No single metric tells the full story. See the FRA:S7C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stenocare AS is a Danish company engaged in the cultivation and production of medical cannabis products through pharmacies and hospitals. The company's business operations include the distribution and sales of imported products to several markets which also includes local cultivation and production of its medical cannabis products. Stenocare is well positioned to become a market leader in Denmark and a vendor in Europe. The company is a supplier of medical cannabis oil for patients in Denmerk, Sweden, UK, Australia and Norway.
40GF Score
Get the complete analysis for FRA:S7C
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S7C has been successfully added to your 
